Form 4: Vaxart CMO Sells Shares for Tax Obligations

Vaxart's Chief Medical Officer, James F. Cummings, disposed of 3,292 common shares to cover tax obligations related to vested restricted stock units.

Summary

• James F. Cummings, Chief Medical Officer of Vaxart, Inc., reported a transaction on March 28, 2026.
• He disposed of 3,292 shares of Vaxart common stock at a price of $0.65 per share.
• This disposition was made to satisfy income tax withholding and remittance obligations in connection with the net settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Cummings beneficially owns 924,177 shares of Vaxart common stock.
• The total beneficial ownership includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard tax-related disposition of vested equity compensation rather than a discretionary sale or a significant change in the executive's investment thesis.

Positives

• The vesting of Restricted Stock Units (RSUs) for the Chief Medical Officer indicates continued employee compensation and retention, aligning executive interests with shareholder value.

Negatives

• The disposition of 3,292 shares, while for tax purposes, reduces the direct beneficial ownership of the Chief Medical Officer.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like tax-related dispositions of vested equity are common across the biotechnology and pharmaceutical industries, reflecting standard executive compensation practices. This specific filing does not indicate any broader industry trends or competitive shifts.

Comparison to Industry Standards

• This transaction is a standard tax-related disposition of vested equity, a common practice for executives across various industries, including biotechnology, to manage compensation and tax liabilities.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related disposition, not a discretionary market sale, and does not signal a change in the executive's confidence in the company.
• Employees: Reflects standard equity compensation practices for executives, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by the Chief Medical Officer to cover tax obligations on vested Restricted Stock Units. It does not reflect a change in the executive's investment sentiment or the company's operational performance, thus providing no new information to warrant a change from a 'hold' position.

Keywords

Vaxart, VXRT, Form 4, insider transaction, stock disposition, Chief Medical Officer, James F. Cummings, RSU, restricted stock units, tax withholding, employee stock purchase plan